+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Rare Disease Genetic Testing Market by Disease Type, Technology, Specialty, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5533238
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Rare Disease Genetic Testing Market grew from USD 1.33 billion in 2023 to USD 1.54 billion in 2024. It is expected to continue growing at a CAGR of 16.15%, reaching USD 3.80 billion by 2030.

Rare disease genetic testing is a crucial segment in the healthcare industry aimed at identifying genetic mutations that cause rare diseases, which affect a small percentage of the population but often have severe impacts. The necessity of genetic testing in this realm stems from its potential to provide early diagnosis, targeted treatments, and better prognoses for conditions that historically go undiagnosed or misdiagnosed. Applications primarily occur within clinical settings for patient diagnosis, personalized medicine development, and new research avenues in genomics. The end-use scope encompasses hospitals, diagnostic laboratories, and research institutes looking to deepen understanding of rare genetic diseases.

Market insights reveal several key growth influencers: advancements in genomic technologies, increased funding for rare disease research, and rising public awareness. Opportunities arise particularly in expanding genomic databases, enhancing diagnostic accessibility, and developing cost-effective testing solutions. Financial incentives from governments and collaborations between biotech firms enhance market prospects. Challenges, however, include the high cost of testing, limited insurance coverage, and the ethical implications of genetic information use, which can impede widespread adoption.

Innovation and research could focus on next-generation sequencing technologies, bioinformatics tools to manage genetic data, and enhancing test precision with AI. Business growth could be achieved by leveraging partnerships with healthcare providers and tech developers to create integrated solutions. The nature of the market is dynamic, with a trend towards personalization and precision medicine, driven by the rapid evolution of genetic testing technologies.

For companies aiming to capitalize on these insights, it is recommended to invest in R&D for novel diagnostic methods, explore strategic partnerships for market expansion, and advocate for policies that support patient access to genetic testing. By doing so, businesses can align with the overarching demand for innovation and accessibility in the rare disease genetic testing market, overcoming challenges while seizing emerging opportunities.

Understanding Market Dynamics in the Rare Disease Genetic Testing Market

The Rare Disease Genetic Testing Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
    • Rising Use in Translational & Genomic Research for Identification of Novel Mutations
    • Government Initiatives for Diagnosis and Treatment of Rare Diseases
  • Market Restraints
    • Ethical Concerns and Access to Limited Information on Rare Disease
  • Market Opportunities
    • Advancements in Genetic Technology to Identify New Rare Disease Genes
    • Favorable Investments for Diagnosis of Rare Genetic Diseases
  • Market Challenges
    • Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test

Exploring Porter’s Five Forces for the Rare Disease Genetic Testing Market

Porter’s Five Forces framework further strengthens the insights of the Rare Disease Genetic Testing Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Rare Disease Genetic Testing Market

External macro-environmental factors deeply influence the performance of the Rare Disease Genetic Testing Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Rare Disease Genetic Testing Market

The Rare Disease Genetic Testing Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Rare Disease Genetic Testing Market

The Rare Disease Genetic Testing Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Laboratory Corporation Of America Holdings, Biora Therapeutics, Inc., 3billion, Inc., Caris Life Sciences, Ambry Genetics Corporation, OPKO Health, Inc., Color Health, Inc., Quest Diagnostics Incorporated, Nonacus Limited, Integrated DNA Technologies, Inc. by Danaher Corporation, Myriad Genetics, Inc., Blueprint Genetics Oy, PerkinElmer Inc., Macrogen, Inc., F. Hoffmann-La Roche Ltd., Variantyx, Inc., Centogene N.V., Fulgent Genetics, Inc., Genomelink, Inc., Illumina, Inc., GeneDx, LLC, Invitae Corporation, Sanofi S.A., Helix OpCo, LLC, Arup Laboratories, The Cooper Companies, Inc., QIAGEN N.V., Realm IDX, Inc., Baylor Genetics, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Disease Type
    • Cancer
    • Cardiovascular Disorders
    • Dermatology Diseases
    • Endocrine & Metabolism Diseases
    • Hematology Diseases
    • Immunological Disorders
    • Musculoskeletal Disorders
    • Neurological Disorders
  • Technology
    • Array Technology
    • FISH
    • Karyotyping
    • Next Generation Sequencing
      • Whole Exome Sequencing
      • Whole Genome Sequencing
    • PCR - Based Testing
    • Sanger Sequencing
  • Specialty
    • Biochemical Genetic Tests
    • Chromosomal Genetic Tests
    • Molecular Genetic Tests
  • End-User
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research Laboratories & CROs
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
5.1.1.2. Rising Use in Translational & Genomic Research for Identification of Novel Mutations
5.1.1.3. Government Initiatives for Diagnosis and Treatment of Rare Diseases
5.1.2. Restraints
5.1.2.1. Ethical Concerns and Access to Limited Information on Rare Disease
5.1.3. Opportunities
5.1.3.1. Advancements in Genetic Technology to Identify New Rare Disease Genes
5.1.3.2. Favorable Investments for Diagnosis of Rare Genetic Diseases
5.1.4. Challenges
5.1.4.1. Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test
5.2. Market Segmentation Analysis
5.2.1. Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases
5.2.2. End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
5.5. Client Customization
6. Rare Disease Genetic Testing Market, by Disease Type
6.1. Introduction
6.2. Cancer
6.3. Cardiovascular Disorders
6.4. Dermatology Diseases
6.5. Endocrine & Metabolism Diseases
6.6. Hematology Diseases
6.7. Immunological Disorders
6.8. Musculoskeletal Disorders
6.9. Neurological Disorders
7. Rare Disease Genetic Testing Market, by Technology
7.1. Introduction
7.2. Array Technology
7.3. FISH
7.4. Karyotyping
7.5. Next Generation Sequencing
7.5.1. Whole Exome Sequencing
7.5.2. Whole Genome Sequencing
7.6. PCR - Based Testing
7.7. Sanger Sequencing
8. Rare Disease Genetic Testing Market, by Specialty
8.1. Introduction
8.2. Biochemical Genetic Tests
8.3. Chromosomal Genetic Tests
8.4. Molecular Genetic Tests
9. Rare Disease Genetic Testing Market, by End-User
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals & Clinics
9.4. Research Laboratories & CROs
10. Americas Rare Disease Genetic Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Rare Disease Genetic Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Rare Disease Genetic Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Burjeel Holdings To Launch Rare Disease Research & Development Project ‘Nader’ In Partnership With US-Based Bridgebio Pharma
13.3.2. NIH Launches USD 140 Million Effort To Investigate Genetic Variation In Normal Human Cells And Tissues
13.3.3. CENTOGENE Launches NEW CentoGenome, A Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases
List of Figures
FIGURE 1. RARE DISEASE GENETIC TESTING MARKET RESEARCH PROCESS
FIGURE 2. RARE DISEASE GENETIC TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2030 (%)
FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. RARE DISEASE GENETIC TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. RARE DISEASE GENETIC TESTING MARKET DYNAMICS
TABLE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 51. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 52. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 53. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 54. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 56. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 58. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 59. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 78. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 80. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 81. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 83. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 85. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 86. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 93. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 95. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 96. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 100. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 101. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 105. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 106. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 109. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 110. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 111. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 115. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 116. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 120. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 121. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 123. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 125. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 126. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 130. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 131. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 138. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 139. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 141. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 142. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 144. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 146. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 147. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 149. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 150. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 151. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 152. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 154. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 156. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 157. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 160. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 161. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 162. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 166. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 167. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 169. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 170. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 171. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 172. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 184. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 186. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 187. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 189. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 190. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 191. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 192. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 194. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 195. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 196. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 197. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 214. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 215. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 216. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 217. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 229. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 230. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 231. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 232. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
TABLE 242. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 244. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Rare Disease Genetic Testing market, which are profiled in this report, include:
  • Laboratory Corporation Of America Holdings
  • Biora Therapeutics, Inc.
  • 3billion, Inc.
  • Caris Life Sciences
  • Ambry Genetics Corporation
  • OPKO Health, Inc.
  • Color Health, Inc.
  • Quest Diagnostics Incorporated
  • Nonacus Limited
  • Integrated DNA Technologies, Inc. by Danaher Corporation
  • Myriad Genetics, Inc.
  • Blueprint Genetics Oy
  • PerkinElmer Inc.
  • Macrogen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Variantyx, Inc.
  • Centogene N.V.
  • Fulgent Genetics, Inc.
  • Genomelink, Inc.
  • Illumina, Inc.
  • GeneDx, LLC
  • Invitae Corporation
  • Sanofi S.A.
  • Helix OpCo, LLC
  • Arup Laboratories
  • The Cooper Companies, Inc.
  • QIAGEN N.V.
  • Realm IDX, Inc.
  • Baylor Genetics
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information